Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TNYA | US
-0.12
-5.88%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.92
2.06
2.08
1.92
Tenaya Therapeutics Inc. a biotechnology company discovers develops and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration gene therapy and precision medicine platforms. The company is developing TN-201 a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301 a small molecule for heart failure with preserved ejection fraction; and TN-401 a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy. It also develops an adeno-associated virus-based gene therapy designed to deliver the dwarf open reading frame gene in the heart for dilated cardiomyopathy; and reprogramming program for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
132.3%1 month
104.3%3 months
89.8%6 months
83.4%-
-
1.27
0.12
0.10
-0.67
-
-
-118.31M
196.12M
196.12M
-
-
-
-
-74.54
12.39
9.23
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.91
Range1M
0.91
Range3M
2.45
Rel. volume
0.85
Price X volume
1.05M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Corbus Pharmaceuticals Holdings Inc | CRBP | Biotechnology | 17.67 | 212.82M | -4.02% | n/a | 11.79% |
| Adaptimmune Therapeutics plc | ADAP | Biotechnology | 0.8238 | 210.68M | -2.24% | n/a | 49.18% |
| Gossamer Bio Inc | GOSS | Biotechnology | 0.921 | 208.36M | -4.26% | n/a | 243.93% |
| OBIO | OBIO | Biotechnology | 5.41 | 204.63M | 1.12% | n/a | 3.29% |
| Kodiak Sciences Inc | KOD | Biotechnology | 3.67 | 193.10M | 1.38% | n/a | 81.94% |
| Cellectis S.A | CLLS | Biotechnology | 1.835 | 191.88M | -3.42% | n/a | 74.14% |
| Sangamo Therapeutics Inc | SGMO | Biotechnology | 0.913 | 190.11M | -0.84% | n/a | 122.82% |
| Candel Therapeutics Inc. Common Stock | CADL | Biotechnology | 5.84 | 187.38M | -3.63% | n/a | -186.13% |
| MediWound Ltd | MDWD | Biotechnology | 17.11 | 184.56M | -2.67% | n/a | 0.00% |
| DiaMedica Therapeutics Inc | DMAC | Biotechnology | 4.29 | 183.39M | -1.15% | n/a | 0.73% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.55 | 145.88M | -0.79% | n/a | 58.43% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.87 | 94.40M | 1.83% | 5.16 | 19.82% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 14.22 | 89.04M | -1.80% | 14.48 | 7.10% |
| Urban One Inc | UONEK | Broadcasting - Radio | 1.01 | 53.54M | -3.35% | n/a | 268.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 13.44 | 20.47M | 4.19% | n/a | 204.46% |
| ILAG | ILAG | Building Products & Equipment | 1 | 18.06M | -2.91% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.67 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.27 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 89.76 | - | Riskier |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 196.12M | - | Emerging |